Search Results - Charles Butts

Refine Results
  1. 1
    Current Landscape of Immunotherapy for the Treatment of Metastatic Non-Small-Cell Lung Cancer

    Current Landscape of Immunotherapy for the Treatment of Metastatic Non-Small-Cell Lung Cancer by Aliyah Pabani, Charles Butts

    Published 2018
    Get full text Get full text
    Revisão
    Save to List
    Saved in:
  2. 2
    Clinical Challenges in Patients with Cancer-Associated Thrombosis: Canadian Expert Consensus Recommendations

    Clinical Challenges in Patients with Cancer-Associated Thrombosis: Canadian Expert Consensus Recommendations by Marc Carrier, Grégoire Le Gal, Sudeep Shivakumar, Vicky Tagalakis, Peter L. Gross, Normand Blais, Charles Butts, Mark Crowther

    Published 2015
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  3. 3
    Randomized phase II trial of gemcitabine–cisplatin with or without trastuzumab in HER2-positive non-small-cell lung cancer

    Randomized phase II trial of gemcitabine–cisplatin with or without trastuzumab in HER2-positive non-small-cell lung cancer by U. Gatzemeier, G. Groth, Charles Butts, Nico van Zandwijk, Frances A. Shepherd, Andrea Ardizzoni, Claire Barton, Parviz Ghahramani, Vera Hirsh

    Published 2003
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  4. 4
    Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: a randomized phase III noninferiority study

    Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: a randomized phase III... by Mace L. Rothenberg, John V. Cox, Charles Butts, Matilde Navarro, Y.-J. Bang, Rakesh Goel, Simon Gollins, Lillian L. Siu, Shelly Laguerre, David Cunningham

    Published 2008
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  5. 5
    Tecemotide in unresectable stage III non-small-cell lung cancer in the phase III START study: updated overall survival and biomarker analyses

    Tecemotide in unresectable stage III non-small-cell lung cancer in the phase III START study: updated overall survival and biomarker analyses by Paul Mitchell, N. Thatcher, Mark A. Socinski, Ewa Wasilewska-Teśluk, K. Horwood, Aleksandra Szczęsna, Claudio Martín, Yu. А. Ragulin, Mauro Zukin, Christoph Helwig, Martin Falk, Charles Butts, Frances A. Shepherd

    Published 2015
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  6. 6
    XELOX (Capecitabine Plus Oxaliplatin): Active First-Line Therapy for Patients With Metastatic Colorectal Cancer

    XELOX (Capecitabine Plus Oxaliplatin): Active First-Line Therapy for Patients With Metastatic Colorectal Cancer by Jim Cassidy, Josep Tabernero, Chris Twelves, René Brunet, Charles Butts, Thierry Conroy, Filippo de Braud, Arié Figer, Johannes Grossmann, Noriaki Sawada, Patrick Schöffski, Alberto Sobrero, Eric Van Cutsem, Eduardo Díaz‐Rubio

    Published 2004
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  7. 7
    Real-World Benefit of Nivolumab in A Canadian Non-Small-Cell Lung Cancer Cohort

    Real-World Benefit of Nivolumab in A Canadian Non-Small-Cell Lung Cancer Cohort by Rosalyn A. Juergens, Caroline Mariano, Jacques Jolivet, Nicholas Finn, J. Rothenstein, M. Neil Reaume, Amir Faghih, Catherine Labbé, Scott Owen, Frances A. Shepherd, J Villeneuve, F. Romeyer, Filippa Pettersson, Charles Butts

    Published 2018
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  8. 8
    Multicenter, Randomized, Phase II Trial of CI-1033, an Irreversible Pan-ERBB Inhibitor, for Previously Treated Advanced Non–Small-Cell Lung Cancer

    Multicenter, Randomized, Phase II Trial of CI-1033, an Irreversible Pan-ERBB Inhibitor, for Previously Treated Advanced Non–Small-Cell Lung Cancer by Pasi A. Jänne, Joachim von Pawel, Roger B. Cohen, Lucio Crinò, Charles Butts, Steven S. Olson, Irene Eiseman, Alberto Chiappori, Beow Y. Yeap, Peter F. Lenehan, Kathy Diener Dasse, Meredith Sheeran, Philip Bonomi

    Published 2007
    Get full text
    Artigo
    Save to List
    Saved in:
  9. 9
    Class III β-Tubulin Expression and Benefit from Adjuvant Cisplatin/Vinorelbine Chemotherapy in Operable Non–Small Cell Lung Cancer: Analysis of NCIC JBR.10

    Class III β-Tubulin Expression and Benefit from Adjuvant Cisplatin/Vinorelbine Chemotherapy in Operable Non–Small Cell Lung Cancer: Analysis of NCIC JBR.10 by P. Sève, Raymond Lai, Keyue Ding, Timothy Winton, Charles Butts, John R. Mackey, Charles Dumontet, Laith Dabbagh, Sarit Aviel‐Ronen, Lesley Seymour, Marlo Whitehead, Ming‐Sound Tsao, Frances A. Shepherd, Tony Reiman

    Published 2007
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  10. 10
    Randomized Phase IIB Trial of BLP25 Liposome Vaccine in Stage IIIB and IV Non–Small-Cell Lung Cancer

    Randomized Phase IIB Trial of BLP25 Liposome Vaccine in Stage IIIB and IV Non–Small-Cell Lung Cancer by Charles Butts, Nevin Murray, Andrew W. Maksymiuk, Glenwood Goss, Ernie Marshall, Denis Soulières, Yvon Cormier, Peter Ellis, Allan Price, Ravinder Sawhney, Mary A. Davis, Janine Mansi, Colum J Smith, D. Vergidis, Peter Ellis, Mary MacNeil, Martin Palmer

    Published 2005
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  11. 11
    Phase II Study of Vandetanib or Placebo in Small-Cell Lung Cancer Patients After Complete or Partial Response to Induction Chemotherapy With or Without Radiation Therapy: National Cancer Institute of Canada Clinical Trials Group Study BR.20

    Phase II Study of Vandetanib or Placebo in Small-Cell Lung Cancer Patients After Complete or Partial Response to Induction Chemotherapy With or Without Radiation Therapy: National... by Andrew Arnold, Lesley Seymour, Michael Smylie, Keyue Ding, Yee Ung, B. Findlay, Christopher W. Lee, Marina Djurfeldt, Marlo Whitehead, Peter Ellis, Glenwood Goss, Adrien Chan, J. Meharchand, Yasmin Alam, Richard Gregg, Charles Butts, Peter Langmuir, Frances A. Shepherd

    Published 2007
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  12. 12
    A randomized, double-blind, phase II study of erlotinib with or without sunitinib for the second-line treatment of metastatic non-small-cell lung cancer (NSCLC)

    A randomized, double-blind, phase II study of erlotinib with or without sunitinib for the second-line treatment of metastatic non-small-cell lung cancer (NSCLC) by Harry J.M. Groen, Mark A. Socinski, Francesco Grossi, Erzsébet Juhász, Cesare Gridelli, Paul Baas, Charles Butts, Ewa Chmielowska, Tiziana Usari, Paulina Selaru, Charles S. Harmon, James A. Williams, Feng Gao, L. Tye, Richard C. Chao, George R. Blumenschein

    Published 2013
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  13. 13
    Randomized Phase III Trial of Vinorelbine Plus Cisplatin Compared With Observation in Completely Resected Stage IB and II Non–Small-Cell Lung Cancer: Updated Survival Analysis of JBR-10

    Randomized Phase III Trial of Vinorelbine Plus Cisplatin Compared With Observation in Completely Resected Stage IB and II Non–Small-Cell Lung Cancer: Updated Survival Analysis of J... by Charles Butts, Keyue Ding, Lesley Seymour, Philip Twumasi‐Ankrah, Barbara Graham, David R. Gandara, David H. Johnson, Kenneth A. Kesler, Mark A. Green, Mark Vincent, Yvon Cormier, Greg G. Goss, B. Findlay, Michael Johnston, Ming‐Sound Tsao, Frances A. Shepherd

    Published 2009
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  14. 14
    Randomized Phase II Study of Gemcitabine Plus Cisplatin or Carboplatin, With or Without Cetuximab, As First-Line Therapy for Patients With Advanced or Metastatic Non–Small-Cell Lung Cancer

    Randomized Phase II Study of Gemcitabine Plus Cisplatin or Carboplatin, With or Without Cetuximab, As First-Line Therapy for Patients With Advanced or Metastatic Non–Small-Cell Lun... by Charles Butts, David Bodkin, Edward L. Middleman, Craig W. Englund, David H. Ellison, Yasmin Alam, Harvey Kreisman, Peter R. Graze, James F. Maher, Helen J. Ross, Peter Ellis, William McNulty, Edward J. Kaplan, Virginie Pautret, Martin R. Weber, Frances A. Shepherd

    Published 2007
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  15. 15
    Symptomatic Toxicities Experienced During Anticancer Treatment: Agreement Between Patient and Physician Reporting in Three Randomized Trials

    Symptomatic Toxicities Experienced During Anticancer Treatment: Agreement Between Patient and Physician Reporting in Three Randomized Trials by Massimo Di Maïo, Ciro Gallo, Natasha B. Leighl, Maria Carmela Piccirillo, Gennaro Daniele, Francesco Nuzzo, Cesare Gridelli, Vittorio Gebbia, Fortunato Ciardiello, Sabino De Placido, Anna Ceribelli, Adolfo Favaretto, A. De Matteis, Ronald Feld, Charles Butts, Jane Bryce, Simona Signoriello, Alessandro Morabito, Gaetano Rocco, Francesco Perrone

    Published 2015
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  16. 16
    Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis

    Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis by Scott Antonia, Hossein Borghaei, Suresh S. Ramalingam, Leora Horn, Javier de Castro, Adam Płużański, Marco Angelo Burgio, Marina Chiara Garassino, Laura Q.M. Chow, Scott Gettinger, Lucio Crinò, David Planchard, Charles Butts, Alexander Drilon, Joanna Wójcik-Tomaszewska, Gregory A. Otterson, Shruti Agrawal, Ang Li, John R. Penrod, Julie R. Brahmer

    Published 2019
    Get full text
    Artigo
    Save to List
    Saved in:
  17. 17
    Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial

    Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial by Charles Butts, Mark A. Socinski, Paul Mitchell, Nick Thatcher, Libor Havel, Maciej Krzakowski, Sergiusz Nawrocki, Tudor‐Eliade Ciuleanu, Lionel Bosquée, José Trigo, Alexander I. Spira, Lise Tremblay, Jan Nyman, Rodryg Ramlau, Gun Wickart-Johansson, Peter Ellis, Oleg Gladkov, José Rodrigues Pereira, Wilfried Eberhardt, Christoph Helwig, Andreas Schröder, Frances A. Shepherd

    Published 2013
    Get full text
    Artigo
    Save to List
    Saved in:
  18. 18
    Vinorelbine plus Cisplatin vs. Observation in Resected Non–Small-Cell Lung Cancer

    Vinorelbine plus Cisplatin vs. Observation in Resected Non–Small-Cell Lung Cancer by Timothy Winton, Robert B. Livingston, David C. Johnson, James R. Rigas, Michael Johnston, Charles Butts, Yvon Cormier, Greg G. Goss, Richard Inculet, Eric Vallières, Willard A. Fry, Drew Bethune, Joseph Ayoub, Keyue Ding, Lesley Seymour, Barbara Graham, Ming‐Sound Tsao, David R. Gandara, Kenneth A. Kesler, Todd L. Demmy, Frances A. Shepherd

    Published 2005
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  19. 19
    Gefitinib Versus Placebo in Completely Resected Non–Small-Cell Lung Cancer: Results of the NCIC CTG BR19 Study

    Gefitinib Versus Placebo in Completely Resected Non–Small-Cell Lung Cancer: Results of the NCIC CTG BR19 Study by Glenwood Goss, Chris J. O’Callaghan, Ian Lorimer, Ming‐Sound Tsao, Gregory A. Masters, James R. Jett, Martin J. Edelman, Rogério Lilenbaum, Hak Choy, Fadlo R. Khuri, Katherine M.W. Pisters, David R. Gandara, Kemp H. Kernstine, Charles Butts, Jonathan Noble, Thomas A. Hensing, Kendrith M. Rowland, Joan H. Schiller, Keyue Ding, Frances A. Shepherd

    Published 2013
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  20. 20
    First-Line Erlotinib Followed by Second-Line Cisplatin-Gemcitabine Chemotherapy in Advanced Non–Small-Cell Lung Cancer: The TORCH Randomized Trial

    First-Line Erlotinib Followed by Second-Line Cisplatin-Gemcitabine Chemotherapy in Advanced Non–Small-Cell Lung Cancer: The TORCH Randomized Trial by Cesare Gridelli, Fortunato Ciardiello, Ciro Gallo, Ronald Feld, Charles Butts, Vittorio Gebbia, Paolo Maione, Floriana Morgillo, Giovenzio Genestreti, Adolfo Favaretto, Natasha B. Leighl, Rafal Wierzbicki, Saverio Cinieri, Yasmin Alam, Salvatore Siena, Giampaolo Tortora, Raffaella Felletti, Ferdinando Riccardi, Gianfranco Mancuso, Antônio Rossi, Flavia Cantile, Ming‐Sound Tsao, Mauro Saieg, Gilda da Cunha Santos, Maria Carmela Piccirillo, Massimo Di Maïo, Alessandro Morabito, Francesco Perrone

    Published 2012
    Get full text Get full text
    Artigo
    Save to List
    Saved in:

Search Tools: